BeOne Medicines jumps on Q1 beat, higher 2026 outlook and BRUKINSA momentum
BeOne Medicines (ONC) rose after reporting first-quarter 2026 revenue of $1.51 billion, up 35% year over year, and GAAP EPS of $1.96. Investors also reacted to $1.1 billion in BRUKINSA revenue (+38%) and a raised 2026 outlook alongside pipeline updates ahead of major oncology presentations.
1. What’s moving the stock today
BeOne Medicines’ ADSs are trading higher after the company released first-quarter 2026 financial results and business updates on May 6, 2026. The update highlighted total revenue of $1.51 billion (+35% year over year), BRUKINSA (zanubrutinib) global revenue of $1.1 billion (+38%), and profitability improvements including GAAP income from operations of about $250 million and diluted GAAP EPS of $1.96 (non-GAAP EPS of $3.24). (stocktitan.net)
2. The numbers investors are keying on
The report points to continued commercial strength in the company’s foundational hematology franchise, with BRUKINSA framed as a key growth driver. The combination of faster revenue growth and expanding operating income in the quarter is fueling optimism that earnings leverage is materializing as scale builds. (stocktitan.net)
3. Pipeline and catalysts that may be adding to upside
Beyond the quarterly beat, BeOne emphasized a rapidly emerging solid-tumor pipeline and noted that more than 20 abstracts across its hematology and solid-tumor programs were accepted for presentation at ASCO, which can serve as a near-term sentiment catalyst for oncology investors. (stocktitan.net)
4. What to watch next
Key follow-ups for the market include how sustainable BRUKINSA’s growth remains across regions, how 2026 operating expense expectations translate into full-year operating leverage, and whether upcoming clinical readouts and conference disclosures shift the competitive outlook in CLL and other hematologic malignancies. (stocktitan.net)